Anti-angiogenesis drug discovery and development. Volume 3

Version imprimée :

PREFACE ; List of Contributors ; Beta-Blocker Therapy for Retinopathy of Prematurity ; 1. WHAT IS ALREADY KNOWN ON THIS TOPIC; 2. WHAT THIS CHAPTER ADDS; 3. INTRODUCTION; 4. FEASIBILITY AND EFFECTIVENESS OF ANTI-ANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY ; Oral Propranolol for Premature Infants with ROP; 4.2. Propranolol Safety and Future in Premature Infants with ROP; 4.3. Ongoing Trials of Propranolol for ROP; 5. FUTURERESEARCH; ABBREVIATIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES. 2.3a. Bevacizumab2.3b. Ramucirumab; 2.3c. Aflibercept; 2.4. Bevacizumab in Adjuvant, Locally Advanced, or Neoadjuvant Treatment of Advanced NSCLC; 3. SMALL MOLECULE ORAL ANTI-ANGIOGENIC COMPOUNDS IN THE FIRST-LINE THERAPY OF NSCLC; 3.1. Inhibition of a Single Angiogenic Pathway Alone; 3.1a. Vandetanib; 3.2a. Cediranib; 3.2b. Sorafenib; 3.2c. Motesanib; 3.2d. Axitinib; 3.2e. Linifanib; 3.2f. Pazopanib; 4. TRIALS OF ORAL ANTI-ANGIOGENIC COMPOUNDS AFTER FAILURE OF FIRST-LINE THERAPY FOR NSCLC; 4.1. Inhibition of VascularEndothelial Growth Factor Receptor Alone; 4.1a. Vandetanib. 4.1b. Cabozantinib4.2a. Nintedanib; 4.2b. Sunitinib; 4.2c. Sorafenib; 4.2d. Linifanib; 4.2e. Cediranib; 5. ANTI-ANGIOGENIC THERAPY IN SCLC; 5.1. Bevacizumab; 5.2. Sunitinib; 5.3. Vandetanib; 5.4. Sorafenib; 5.5. Thalidomide and Other Immunomodulatory Agents; 5.6. Aflibercept; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Angiogenesis in Hepatocellular Carcinoma (HCC) and its Potential Applications in the Development of Anti-HCC Drugs ; 1. INTRODUCTION; 2. ANGIOGENESIS AND ITS REGULATION IN HEPATOCELLULARCARCINOMA; 2.1. Angiogenesis Factors in Hepatocellular Carcinoma. 6.5. KTS Cyclic Peptides Increase Survival of Mice with Melanoma TumorsCONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Current Status of Anti-Angiogenic Therapy in the Clinical Management of Lung Cancer ; 1. ANGIOGENESIS IN THE PATHOGENESIS OF LUNG CANCER; 2. MONOCLONAL ANTIBODIES AS ANTI-ANGIOGENIC THERAPY; 2.1. Bevacizumab in Combination with Platinum-Based Chemotherapy for the First-Line Therapy of NSCLC; 2.2. Other Intravenous Anti-Angiogenic Compounds in First-Line Therapy for NSCLC; 2.3. TheRole of Anti-Angiogenic Therapy Upon Disease Progression